The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Agree that itās a total s.it show here these days. Must disagree that you donāt normally reply - most of the chat here is you constantly replying to the likes of MrI, 121, Stu and the other twats.
I think I now only have about 10 posters whose comments I can read - the rest are binned.
Haywain is by far the best poster on this board and Iām very grateful for his input.
So you think that we may get to Ā£2 but refuse to buy at around 54p?? Have you appplied for this years businessman of the year award ? Bitter clown who wonāt take responsibility for his own actions. If you donāt think the price will increase why would you still hold ?
Points 1,2 and 3 completely agree.
Point 4 - not sure on this one as we may end up with multiple small raises and the SP would likely not increase due to the uncertainty of when the next 1 would be.
Point 5 - for me PrimaryBid isnāt great as most PIās wouldnāt be interested in buying at a premium. Why not buy cheaper on the open market ? Also Iām not sure what PrimaryBid charge the company to use their service.
Seriously ! - where did I say it was a bad investment ? Got a decent holding and not sold 1 share. Iām just not expecting big gains for some time. Maybe take a look at yourself and all your previous predictions.
Donāt want to fall out as you post some decent stuff. I have my opinion and you have yours. Best of luck going forward.
Totally agree with all of your comments Haywain but sometimes pie in the sky figures need to be reigned in and a more realistic approach taken. I have full faith that Hemo will come good from a patient and shareholder perspective but these things take time (and a lot of money).
So you reckon 3m is enough to complete a whole trial (all phases) ?
If you think youāre getting the below at a discount then think again and, as I was once told - donāt be so thick.
An additional and under-reported opportunity to reduce the price of CAR T-cells lies in reducing the total cost of the delivery of cellular therapies to patients. Because of the complexity of delivering cellular therapies, medical centers enter elaborate, multistep negotiations with payers to pay for the entire package of care, typically in a bundle. Treating a patient with a CAR T-cell therapy generally requires (1) procedural and laboratory pretesting (eg, echocardiography and pulmonary function testing), (2) suitability review by physicians and social workers, (3) placement of an apheresis catheter (typically under a local anesthetic), (4) leukapheresis, (5) CAR T-cell production and return shipment to the medical center, (6) treatment with lymphodepleting chemotherapy, (7) treatment with CAR T-cell therapy, (8) response assessments (eg, in lymphoma with fluorodeoxyglucose-positron emission tomography scans, or in ALL with bone marrow biopsy plus flow cytometry), and (9) recovery from toxicities.
jhfh - it definitely is not enough to run a complete trial with 20 patients.
iāll be surprised if itās enough for phase 1 let alone the remaining phases. totally agree that theyāll need 10ās of millions and 3m is like ******* into the wind.
Hiki - on your comment ā Mr India made the outrageous claim about an hour ago that Hemo were fully funded for trials and nobody says a thingā - itās probably because most on here have him in the bin so have no idea what heās saying. Heās a menace who changes his stance depending whether he wants to buy or sell.
Sorry JHFH but I have to disagree and that 3m is not enough to run a trial for 20 patients. It may be enough to get us part way through phase 1 but no more. IMO we need a collaboration asap to avoid another round of funding.